Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trialBRITISH JOURNAL OF DERMATOLOGYIF9.62023-07-1832OA
Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitisBRITISH JOURNAL OF DERMATOLOGYIF9.62023-06-200PRE
Treatment with amlitelimab-a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody-reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitisBRITISH JOURNAL OF DERMATOLOGYIF9.62023-01-255PRE
Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assayBRITISH JOURNAL OF DERMATOLOGYIF9.62023-01-250PRE
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005CLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52022-03-0126OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向